NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types
NeoGenomics, Inc. (NEO)
Last neogenomics, inc. earnings: 4/28 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.neogenomics.com
Company Research
Source: Business Wire
We estimate that MRD represents a $20+ billion addressable market, growing at 30% annually, which we believe is less than 10% penetrated FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of RaDaR® ST, its circulating tumor DNA (ctDNA) assay for detecting molecular residual disease (MRD).“RaDaR ST represents an important advancement in MRD testing, a rapidly growing market that remains largely untapped,” said Tony Zook, CEO of NeoGenomics. “By providing patient-specific molecular insights, the test enables clinicians to detect residual disease and recurrence sooner than conventional imaging, supporting more informed treatment decisions at each stage of care. Our goal with RaDaR ST is to give providers reliable, actionable results that can be incorporated into clinical practice and research programs, helping support informed clinical decisions and enable ea
Show less
Read more
Impact Snapshot
Event Time:
NEO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NEO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NEO alerts
High impacting NeoGenomics, Inc. news events
Weekly update
A roundup of the hottest topics
NEO
News
- 3 Reasons to Avoid NEO and 1 Stock to Buy Instead [Yahoo! Finance]Yahoo! Finance
- NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types [Yahoo! Finance]Yahoo! Finance
- NeoGenomics (NASDAQ:NEO) had its "overweight" rating reaffirmed by analysts at Piper Sandler.MarketBeat
- NeoGenomics (NASDAQ:NEO) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat
- Assessing NeoGenomics (NEO) Valuation After Recent Share Price Weakness [Yahoo! Finance]Yahoo! Finance
NEO
Earnings
- 2/17/26 - Beat
NEO
Sec Filings
- 2/24/26 - Form 4
- 2/24/26 - Form 4
- 2/24/26 - Form 4
- NEO's page on the SEC website